<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559685</url>
  </required_header>
  <id_info>
    <org_study_id>2020-11</org_study_id>
    <secondary_id>21-500-032-34-38</secondary_id>
    <nct_id>NCT04559685</nct_id>
  </id_info>
  <brief_title>Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma</brief_title>
  <official_title>A Phase 0, First in Human, Open-label Study of Intravenous Aminolevulinic Acid HCl (ALA) and MR-Guided Focused Ultrasound Device (MRgFUS) in Participants With Recurrent High Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nader Sanai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barrow Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ivy Brain Tumor Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SonALAsense, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 0 single center, first in human, open-label study of ascending energy doses of&#xD;
      sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety&#xD;
      and efficacy in up to 30 participants with recurrent HGG. Eligible participants who are&#xD;
      scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA)&#xD;
      approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological changes associated with the sonodynamic therapy</measure>
    <time_frame>Intraoperatively 2, 4, or 6 days post sonodynamic therapy</time_frame>
    <description>The percentage (%) of Cleaved Caspase-3, MIB-1 level, GammaH2Ax of the surgical tissue will be quantified and compared to intra-patient control specimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic evidence of tumor physiological imaging changes associated with sonodynamic therapy</measure>
    <time_frame>Pre and 14 Days Post-operative scan</time_frame>
    <description>Dynamic Contrast Enhanced (DCE)-MRI data to quantify permeability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic evidence of tumor physiological imaging changes associated with sonodynamic therapy</measure>
    <time_frame>Pre and 14 Days Post-operative scan</time_frame>
    <description>Dynamic Susceptibility Contrast (DSC)-MRI data to quantify perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic evidence of tumor physiological imaging changes associated with sonodynamic therapy</measure>
    <time_frame>Pre and 14 Days Post-operative scan</time_frame>
    <description>Diffusion Weighted Imaging (DWI) data to evaluate cellularity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify oxidative stress in tissue exposed to sonodynamic therapy in recurrent high-grade glioma patients.</measure>
    <time_frame>Intraoperatively 2, 4, or 6 days post sonodynamic therapy</time_frame>
    <description>To quantify markers for oxidative stress (Protein oxidation (Protein Carbonyl Content), Lipid peroxidation (4-hydroxynonenal and MDA), DNA damage (8-hydroxyguanosine),General (GSH, GSSG, Cys, CySS) in the brain tumor tissue (2-, 4- and 6-days post SDT) (both in SDT and control fractions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of MRgFUS</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of SDT treatments in which the MRgFUS system works as planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of MRgFUS</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of treatments in which procedure deviations were noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 30 days after the last study dose</time_frame>
    <description>Number and incidence of drug-related toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 30 days after the last study dose</time_frame>
    <description>Adverse device effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Arm A Dose-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Time-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm B, the time-escalation cohort, the SONALA-001 and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)</intervention_name>
    <description>SONALA-001(ALA) given 6-7 hours prior to receiving the MRgFUS.</description>
    <arm_group_label>Arm A Dose-escalation</arm_group_label>
    <arm_group_label>Arm B Time-escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prior resection of histologically diagnosed high-grade gliomas (III and IV) defined as&#xD;
             participants who have progressed on or following standard (Stupp regimen) therapy,&#xD;
             which includes maximal surgical resection, temozolomide, and fractionated&#xD;
             radiotherapy.&#xD;
&#xD;
          2. Recurrence must be confirmed by diagnostic biopsy with local pathology review or&#xD;
             contrast-enhanced MRI with positive perfusion.&#xD;
&#xD;
          3. Have measurable disease preoperatively, defined as at least 1 contrast-enhancing&#xD;
             lesion, with a volume of at least 6 cm3 and ≤ 20cm3 of targeted treatment area.&#xD;
&#xD;
          4. Age ≥18 at time of consent.&#xD;
&#xD;
          5. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG)&#xD;
             scale (Oken et al. 1982).&#xD;
&#xD;
          6. Ability to swallow oral medications.&#xD;
&#xD;
          7. Has adequate bone marrow and organ function as defined by the following laboratory&#xD;
             values (as assessed by the local laboratory for eligibility)&#xD;
&#xD;
             Adequate bone marrow function:&#xD;
&#xD;
               -  absolute neutrophil count ≥1,000/mcL&#xD;
&#xD;
               -  Platelets (at time of surgery) ≥100,000/mcL&#xD;
&#xD;
               -  hemoglobin ≥8.0 g/dL Participants may receive erythrocyte transfusions to achieve&#xD;
                  this hemoglobin level at the discretion of the investigator.&#xD;
&#xD;
             Adequate hepatic and renal function:&#xD;
&#xD;
               -  total bilirubin ≤1.5 X ULN. Participants with Gilbert's syndrome with a total&#xD;
                  bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.&#xD;
&#xD;
               -  AST(SGOT) ≤3 X institutional ULN&#xD;
&#xD;
               -  ALT(SGPT) ≤3 X institutional ULN&#xD;
&#xD;
               -  GGT ≤3 X institutional ULN&#xD;
&#xD;
               -  Serum creatinine ≤1.5 X institutional ULN&#xD;
&#xD;
          8. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or&#xD;
             participant has had a hysterectomy.&#xD;
&#xD;
          9. For females of reproductive potential: use of highly effective contraception for at&#xD;
             least 1 month prior to screening and agreement to use such a method during study&#xD;
             participation and for an additional 3 months after the end of treatment&#xD;
             administration.&#xD;
&#xD;
         10. For males of reproductive potential: use of condoms or other methods to ensure&#xD;
             effective contraception with partner and for an additional 1 month after the end of&#xD;
             treatment administration. A condom is required to be used also by vasectomized men as&#xD;
             well as during intercourse with a male partner to prevent delivery of the drug via&#xD;
             seminal fluid.&#xD;
&#xD;
         11. Participants who received chemotherapy must have recovered (Common Terminology&#xD;
             Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy&#xD;
             except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A&#xD;
             washout period of at least 21 days is required between last chemotherapy dose and Day&#xD;
             1 (provided the patient did not receive radiotherapy).&#xD;
&#xD;
         12. Participants who received radiotherapy must have completed and fully recovered from&#xD;
             the acute effects of radiotherapy. A washout period of at least 14 days is required&#xD;
             between end of radiotherapy and Day 1.&#xD;
&#xD;
         13. Ability to understand and the willingness to sign a written informed consent document&#xD;
             (personally or by the legally authorized representative, if applicable).&#xD;
&#xD;
         14. Has voluntarily agreed to participate by giving written informed consent (personally&#xD;
             or via legally authorized representative(s), and assent if applicable). Written&#xD;
             informed consent for the protocol must be obtained prior to any screening procedures.&#xD;
             If consent cannot be expressed in writing, it must be formally documented and&#xD;
             witnessed, ideally via an independent trusted witness.&#xD;
&#xD;
         15. Willingness and ability to comply with scheduled visits, treatment plans, Lifestyle&#xD;
             Considerations, laboratory tests and other procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at&#xD;
             time of initiating study treatment), fungal infection, or detectable viral infection&#xD;
             (such as known human immunodeficiency virus positivity or with known active hepatitis&#xD;
             B or C [for example, hepatitis B surface antigen positive]. Screening is not required&#xD;
             for enrollment.&#xD;
&#xD;
          2. Have had a recent (≤3 months prior to first dose of study drug) transient ischemic&#xD;
             attack or stroke.&#xD;
&#xD;
          3. Significant vascular disease (e.g. aortic aneurysm)&#xD;
&#xD;
          4. Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          5. Diagnosis of porphyria&#xD;
&#xD;
          6. Unstable angina and/or congestive heart failure within the last 6 months&#xD;
&#xD;
          7. Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
          8. Serious and inadequately controlled cardiac arrhythmia&#xD;
&#xD;
          9. Acute exacerbation of chronic obstructive pulmonary disease&#xD;
&#xD;
         10. Inability to undergo MRI (e.g., presence of a pacemaker)&#xD;
&#xD;
         11. Pregnancy or breastfeeding&#xD;
&#xD;
         12. Has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment&#xD;
             of the investigator, would preclude participation in this study.&#xD;
&#xD;
         13. Simultaneous use of other potentially phototoxic substances (e.g. tetracyclines,&#xD;
             sulfonamides, fluoroquinolones, hypericin extracts)&#xD;
&#xD;
         14. Hypersensitivity against porphyrins&#xD;
&#xD;
         15. Treatment with another investigational drug within 30 days prior to enrollment or&#xD;
             within 5 half-lives of the investigational product, whichever is longer.&#xD;
&#xD;
         16. Has an Overall Skull Density Ratio of 0.45 (±0.05) or less as calculated from the&#xD;
             screening CT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Sanai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital and Medical Center, Phoenix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phase 0 Navigator</last_name>
    <phone>602-406-8605</phone>
    <email>research@ivybraintumorcenter.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phase 0 Navigator</last_name>
      <phone>602-406-8605</phone>
      <email>research@ivybraintumorcenter.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Hospital and Medical Center, Phoenix</investigator_affiliation>
    <investigator_full_name>Nader Sanai</investigator_full_name>
    <investigator_title>Deputy Director, Ivy Brain Tumor Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

